Lower Healthcare Costs Associated with the Use of a Single-Pill ARV Regimen in the UK, 2004-2008

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Beck, Eduard J ^a,b,g   Mandalia, Sundhiya ^a,c,g   Sangha, Roshni ^a   Youle, Mike ^a,d   Brettle, Ray ^e   Gompels, Mark ^f   Johnson, Margaret ^d   Pozniak, Anton ^g   Schwenk, Achim ^h   Taylor, Stephen ⁱ   Walsh, John ^j   Wilkins, Ed ^k   Williams, Ian ^l   Gazzard, Brian ^a,c,g  

^a NPMS HHC CIC   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e WESTERN GENERAL HOSPITAL   (United Kingdom)

^f SOUTHMEAD HOSPITAL   (United Kingdom)

^g CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^h NORTH MIDDLESEX UNIVERSITY HOSPITAL   (United Kingdom)

ⁱ BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^j ST MARY S HOSPITAL   (United Kingdom)

^k NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; HEALTH CARE COST; HOSPITAL COST; HUMAN; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; UNITED KINGDOM; VIRUS LOAD;

ADENINE; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; ORGANOPHOSPHORUS COMPOUNDS; OXAZINES; PROPORTIONAL HAZARDS MODELS; VIRAL LOAD;

EID: 84868135041     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047376     Document Type: Article

References (38)

1. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, et al. (2003) Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.3506109 cells/L. Ann Intern Med 139: 810-816.
2. Bangsberg DR, Perry S, Charlebois ED, Clark RA, Roberston M, et al. (2001) Nonadherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 15: 1181-1183.
3. DeJesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, et al. (2009) Simplification of antiretroviral therapy to a single tablet regimen consisting of efavirenz, emtricitabine and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. J Acquir Immune Defic Syndr 51: 163-174.
4. Hodder SL, Mounzer K, DeJesus E, Ebrahimi R, Grimm K, et al. (2010) Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single tablet regimen of efavirenz, emtricitabine and tenofovir DF. AIDS Patient Care STDs 24: 115-125.
5. Airoldi M, Zaccarelli M, Bisi L, Bini T, Antinori A, et al. (2010) One-pill once-aday HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 4: 115-125.
6. Bangsberg DR, Ragland K, Monk A, Deeks SG, (2010) A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 24: 2835-2840.
7. Gupta AK, Arshad S, Poulter NR, (2010) Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents a meta-analysis. Hypertension 55: 399-407.
8. World Health Organization (2003) Fixed-dose combinations for HIV/AIDS, tuberculosis and malaria. Report of a meeting held 16-18 December 2003, Geneva Available: http://apps.who.int/medicinedocs/en/d/Js6172e/. Accessed 2012 Apr 29.
9. Beck EJ, Mandalia S, (2003) The cost of HIV treatment and care in England since HAART: Part 2. British Journal of Sexual Medicine 27 (2):: 21-23.
10. UNAIDS/PEPFAR (2007) Interim guidelines on protecting the confidentiality and security of HIV information: proceedings from a workshop, 15-17 May 2006, Geneva, Switzerland. 15 May Available: http://data.unaids.org/pub/manual/2007/confidentiality_security_interim_guidelines_15may2007_en.pdf. Accessed 2012 Apr 29.
11. Rubin DB (1987) Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons, Inc.
12. Schafer JL (1997) Analysis of incomplete multivariate data. New York: Chapman and Hall.
13. Mandalia S, Parmar D, Fisher M, Pozniak A, Tang A, et al. (2002) Naïvely Changing HAART. HIV Medicine 3: 254-262.
14. Thakkar B, Hur K, Henderson WG, Oprian C (1998) A Method to Generate Kaplan-Meier and Adjusted Survival Curves using SAS. SUGI 23, Paper 226, March 22-25, Nashville, USA. Available: http://www2.sas.com/proceedings/sugi23/Stats/p226.pdf Accessed 2012 Apr 29.
15. Beck EJ, Miners AH (2001) Effectiveness and efficiency in the delivery of HIV services: economic and related considerations. In: Gazzard B, Johnson M, Miles A, editors. The Effective management of HIV Disease. Aesculapius Medical Press, London: 113-38.
16. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, et al. (2004) The cost-effectiveness of HAART, Canada 1991-2001. AIDS 18: 2411-9.
17. Badri M, Maartens G, Mandalia S, Bekker L-G, Penrod JR, et al. (2006) Cost-effectiveness of highly active antiretroviral therapy in South Africa. Plos Medicine January 3: e4 Accessed 29 April 2012 Available:http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0030004.
18. Beck EJ, Mandalia M, Lo G, Sharott P, Youle M, et al. (2011) Cost-effectiveness of early treatment with first-line NNRTI-based HAART regimens in the UK, 1996-2006. PLoS ONE 6 (5): e20200. Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0020200. Accessed 2012 Apr 29.
19. Tolley K, Gyldmark M, (1993) The treatment and care costs of people with HIV infection and AIDS: development of a standardized cost framework for Europe,. Health Policy 24: 55-70.
20. Tolley K, Gyldmark M (1995) A standerdised framework for costing HIV and AIDS treatment in Europe in Fitzsimons D, Hardy V and Tolley K The Economic and Social Impact of AIDS in Europe, Cassell, London: 54-62.
21. Postma MJ, Tolley K, Leidl RM, Downs AM, Beck EJ, et al. (1997) Hospital Care for Persons with AIDS in the European Union: assessment of current and future impact controlled for severity-stages. Health Policy 41: 157-76.
22. Beck EJ, Mandalia S, Mandalia R, Youle M, Gazzard B (2010) Use and Cost of HIV Service Provision in UK NPMS-HHC Sites: Aggregate Analyses January 1996 to December 2008. NPMS-HHC Coordinating and Analytic Centre CIC, London, UK.
23. Scourfield A, Zheng J, Chinthapalli S, Waters L, Martin T, et al. (2012) Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS 26: 1399-1401.
24. Beck EJ, Mandalia S, Sangha R, Sharott P, Youle M, et al. (2011) The Cost-effectiveness of Early Access to HIV Services and Starting cART in the UK 1996-2008. PLoS ONE 6 (12):: e27830 Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0027830. Accessed 2012 Apr 29.
25. World Health Organization (2010) Towards Universal Access. Scaling up priority HIV/AIDS interventions in the health sector 2010 Progress Report, Geneva 2010. Available: http://whqlibdoc.who.int/publications/2010/9789241500395_eng.pdf. Accessed 2012 Apr 29.
26. Panel on antiretroviral guidelines for adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services pp. 1-239; E1-4 Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2012 Apr 29.
27. Beck EJ, Mays N (2006) Some Lessons Learned. In: Beck EJ, Mays N, Whiteside A, Zugina J, editors. The HIV Pandemic: local and global implications. Oxford, UK: Oxford University Press. 769-772 p.
28. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, et al. (2006) Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS 20: 1163-1169.
29. Duse AG, Morar A, Landman I, Vermaak WJH, Schoeman H, et al. (2008) Short-term effectiveness and safety of HAART in the form of a generic fixed-dose combination of Stavudine, Lamivudine and Nevirapine (Triviro) in HIV-1-infected adults in Zimbabwe. The Southern African Journal of HIV Medicine 9: 51-56.
30. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. (2006) Adherence to antiretroviral therapy in sub-saharan Africa and North America: A meta-analysis. JAMA 296: 679-690.
31. Maggiolo F, Airoldi M, Trotta MP, Sette P, Bisi L, et al. (2008) Effect of a fixed-dose combination of Emtricitabine, Tenofovir and Efavirenz on adherence and treatment acceptability (ADONE study). Journal of the International AIDS Society 11 (Suppl 1):: P167.
32. Cohen C, Davis KL, Meyers JL (2011) Effect of daily antiretroviral pill burden on healthcare utilization and costs in United States medicaid enrollees with HIV. 13th European AIDS Conference (EACS), October 12-15, 2011, Belgrade, Serbia Poster PE7.5/7.
33. Sax PE, Meyers JL, Mugavero M, Davis KL, (2012) Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE 7 (2):: e31591.
34. Colombo GL, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, et al. (2011) Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. ClinicoEconomics and Outcomes Research 2011: 3 197-205.
35. WHO+UNAIDS (2011) The Treatment 2.0 framework for action: catalysing the next phase of treatment, care and support, WHO, Geneva. Available: http://whqlibdoc.who.int/publications/2011/9789241501934_eng.pdf. Accessed 2012 Aug 12.
36. Beck EJ, Avila C, Gerbase S, Harling G, De Lay P, (2012) Counting the cost of not costing HIV health facilities accurately: pay now or pay more later. PharmacoEconomics 30 (10):: 1-16.37.
37. Rossi V, Bisola O, Hirschhorn L (2012) World Health Organization's 2010 Recommendations for HIV Treatment: National Guideline Revision Challenges and Lessons Learned. Arlington, VA: USAID's AIDS Support and Technical Assistance Resources, AIDSTAR-One, Task Order 1. Available: http://www.aidstar-one.com/focus_areas/treatment/resources/technical_briefs/who_2010_guidelines. Accessed 2012 Apr 29.
38. Mandalia S, Mandalia R, Lo G, Chadborn T, Sharott P, et al. (2010) Rising Population Cost for Treating People Living with HIV in the UK, 1997-2013,. PLoS ONE 5 (12):: e15677 Available: http://www.plosone.org/article/info:doi/10.1371/journal.pone.0015677. Accessed 2012 Apr 29.